MGNX earnings call for the period ending June 30, 2020.
News & Analysis: MacroGenics
Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.
Traders are exiting the stock as the ASCO 2020 conference gets underway.
Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.
Here's what's behind their impressive market performances.
MGNX earnings call for the period ending March 31, 2020.
The company could receive an FDA go-ahead on its lead drug candidate as soon as this year.
MGNX earnings call for the period ending December 31, 2019.
Industry watchers are skeptical that the company's lead drug candidate can succeed.
MGNX earnings call for the period ending September 30, 2019.